Evaluating sensing technology for neural implant applications

MintNeuro, a pioneer in neural implant technology, is addressing critical unmet healthcare needs in the neurological sector. Our focus is on developing advanced semiconductor technology to revolutionise neuromonitoring, brain-computer interfaces (BCIs), and neuromodulation implants. This innovation aims to enhance functionality, efficiency, and reduce invasiveness of implantable treatments for Drug-Resistant Epilepsy (DRE), paralysis, neurodegeneration, mental health disorders, and other severe neurological conditions.

Leveraging our expertise and the success in developing the DREAM sensing chip for epilepsy neuromonitoring---funded by the NIHR---we propose to extend its application beyond epilepsy to a broader spectrum of neurological conditions.

Led by Dr. Dorian Haci (CEO), our team comprises members with extensive experience in neural interfaces, implantable medical devices, and semiconductor technology. Given MintNeuro is an Imperial College London spinout with agreements for facility access in place, the project will utilise the resources and facilities of the Centre for Bio-Inspired Technology at Imperial.

Moreover, our collaboration with critical partners providing electronic services, manufacturing, and packaging ensures quality and efficiency in our deliverables. Governed under an ISO13485 Quality Management System, our project framework guarantees structured and quality-assured development.

Our target market, positioned at the intersection of the "Active Implantable Medical Device" and "Neurotechnology" industries, shows a high growth potential. Our entry strategy involves collaborating with UK-based and international medical device SMEs and BCI leaders, and later expanding to larger multinational medtech companies.

With regulatory infrastructure already in place and exclusive licenses on key patents, we are well-positioned to overcome barriers and assert our freedom-to-operate in this rapidly expanding market.